Back
SpringWorks Therapeutics Quote, Financials, Valuation and Earnings
![](/images/offers/ims/large/offer17.jpg)
1-day winners in this choppy market
Get the 1-day winners strategy here.
Sell
22
SWTX
SpringWorks Therapeutics
Last Price:
38.69
Seasonality Move:
12.83%
7 Day Trial
ALL ACCESS PASS
$
7
![](/images/offers/ims/large/offer18.jpg)
Generate income in just 1 day
Here's the 1-day income strategy for freeSpringWorks Therapeutics Price Quote
$38.69
-0.01 (-3.71%)
(Updated: September 7, 2024 at 6:57 AM ET)
SpringWorks Therapeutics Key Stats
Sell
22
SpringWorks Therapeutics (SWTX)
is a Sell
Day range:
$38.46 - $40.54
52-week range:
$18.00 - $53.92
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
5.16%
Volume:
320.5K
Avg. volume:
890.9K
1-year change:
39.51%
Market cap:
$2.9B
Revenue:
$5.4M
EPS:
$-4.44
How Much Does SpringWorks Therapeutics Make?
Data Unavailable
Is SpringWorks Therapeutics Growing As A Company?
Data Unavailable
SpringWorks Therapeutics Stock Price Performance
-
Did SpringWorks Therapeutics Stock Go Up Last Month?
SpringWorks Therapeutics share price went up by 16.5% last month -
Did SWTX's Share Price Rise Over The Last Year?
SWTX share price rose by 39.51% over the past 1 year
What Is SpringWorks Therapeutics 52-Week High & Low?
-
What Is SpringWorks Therapeutics’s 52-Week High Share Price?
SpringWorks Therapeutics has traded as high as $53.92 over the past 52 weeks -
What Is SpringWorks Therapeutics’s 52-Week Low Share Price?
SpringWorks Therapeutics has traded as low as $18.00 over the past 52 weeks
SpringWorks Therapeutics Price To Free Cash Flow
Data Unavailable
Is It Risky To Buy SpringWorks Therapeutics?
-
How Much Debt Does SpringWorks Therapeutics Have?
Total long term debt quarterly is $0 -
How Much Cash Does SpringWorks Therapeutics Have?
Cash and short term investments quarterly total is $383.9M -
What Is SpringWorks Therapeutics’s Book Value Per Share?
Book value per share is 7.50
Is SpringWorks Therapeutics Cash Flow Positive?
-
What Is SWTX Cash Flow From Operations?
Cash flow from operations (TTM) is -$233.9M -
What Is SpringWorks Therapeutics’s Cash Flow From Financing?
Cash flow from financing (TTM) is $301.6M -
What Is SpringWorks Therapeutics’s Cash Flow From Investing?
Cash flow from investing (TTM) is -$102.9M
SpringWorks Therapeutics Return On Invested Capital
-
Is Management Doing A Good Job?
SWTX return on invested capital is -57.97% -
What Is SpringWorks Therapeutics Return On Assets?
ROA measures how assets are converting to revenues and is -50.43% -
What Is SWTX Return On Equity?
ROE is a measure of profitability and is -57.97%
SpringWorks Therapeutics Earnings Date & Stock Price
-
What Is SpringWorks Therapeutics's Stock Price Today?
A single share of SWTX can be purchased today for 38.70 -
What Is SpringWorks Therapeutics’s Stock Symbol?
SpringWorks Therapeutics trades on the nasdaq under the ticker symbol: SWTX -
When Is SpringWorks Therapeutics’s Next Earnings Date?
The next quarterly earnings date for SpringWorks Therapeutics is scheduled on November 1, 2024 -
When Is SWTX's next ex-dividend date?
SpringWorks Therapeutics's next ex-dividend date is September 7, 2024 -
How To Buy SpringWorks Therapeutics Stock?
You can buy SpringWorks Therapeutics shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
SpringWorks Therapeutics Competitors
-
Who Are SpringWorks Therapeutics's Competitors?
Below is a list of companies who compete with SpringWorks Therapeutics or are related in some way:
SpringWorks Therapeutics Dividend Yield
-
What Is SWTX Dividend Yield?
SpringWorks Therapeutics’s dividend yield currently is 0% -
What Is SpringWorks Therapeutics’s Payout Ratio?
SpringWorks Therapeutics’s payout ratio is 0% -
When Did SpringWorks Therapeutics Last Pay A Dividend?
The latest dividend pay date is September 7, 2024 -
What Is SpringWorks Therapeutics’s Dividend Per Share?
SpringWorks Therapeutics pays a dividend of $0.00 per share
SpringWorks Therapeutics Analyst Estimates
YoY Growth | Past Surprise | |
---|---|---|
EPS: | 0% | 49.3% |
Revenue: | 0% | 72.74% |
Analyst Recommendations
Buy Recommendations: | 4 |
---|---|
Hold Recommendations: | 0 |
Sell Recommendations: | 0 |
Price Target: | 68.13 |
Upside from Last Price: | 76.03% |